NatureRevClinOncol
The latest clinical diagnostic, treatment & personalized medicine advances & more from Nature Reviews Clinical Oncology, a reviews journal. Tweets by the eds.
Last synced from Twitter 1258d ago
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Nature Medicine 92d 8 tweets
Preliminary results from the Beat AML umbrella trial demonstrates the feasibility and efficacy of applying prospective genomic profiling for matching newly diagnosed patients with AML with targeted therapies.
2
NatureRevClinOncol BEAT-AML trial provides proof of principle for a precision medicine for pts aged >60 yrs with AML: 95% has molecular profiling completed within 7 days and 30-day mortality was lower in the 57% of pts who received targeted therapy (3.7% vs 20.4% with SOC) 91d
Consequences of COVID-19 for cancer care — a CRUK perspective
Nature Reviews Clinical Oncology 95d 1 tweets
We reflect on the past 10 months of clinical activity in oncology in the UK during the COVID-19 pandemic and suggest how services can be protected during subsequent waves of infection.
1
NatureRevClinOncol In a Comment now live, and Emma Greenwood discuss the consequences of #COVID19 in #oncology from a CRUK perspective, with a message that resonates globally 95d
Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia
Nature Cancer 98d 3 tweets
Ferrando and colleagues analyze matched diagnostic and relapsed acute lymphocytic leukemia by whole-genome sequencing, and perform in vitro genome-wide CRISPR screens, to examine alterations associated with chemotherapy resistance.
1
NatureRevClinOncol Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia: #leusm #hemeonc 98d
The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells
Cancer Discovery 102d 1 tweets
Glioblastoma is a universally lethal cancer driven by glioblastoma stem cells (GSCs). Here, we interrogated N6-methyladenosine (m6A) mRNA modifications in GSCs by methyl RNA-immunoprecipitation followed by sequencing (meRIP-seq) and transcriptome...
1
NatureRevClinOncol The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells: #btsm 102d
COVID-19 in patients with cancer: managing a pandemic within a pandemic
Nature Reviews Clinical Oncology 102d 3 tweets
The coronavirus disease 2019 (COVID-19) pandemic has disrupted health care worldwide. Patients with cancer seem to be particularly susceptible to morbidities and mortality from this novel disease. No COVID-19-specific therapy currently seems to...
1
NatureRevClinOncol New article by Leora Horn & Marina Garassino now live online: 'COVID-19 in patients with cancer: managing a pandemic within a pandemic' - #Covid19 #COVID19nCancer 102d
Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer
Clinical Cancer Research 105d 3 tweets
Purpose: We report the final analysis of JVDL ([NCT02789345][1]), which examined the combination of the EGFR TKI osimertinib plus the VEGFR2-directed antibody ramucirumab in patients with T790M-positive EGFR-mutant NSCLC. Experimental Design: This...
1
NatureRevClinOncol In phase I study of ramucirumab plus osimertinib in pts with advanced-stage EGFR T790M-mutant NSCLC, the ORR was 76% (69% in those with CNS mets). The mDOR was 13.4 months; mPFS was 10.9 and 14.7 months in those with and without CNS mets, respectively 103d
Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence
Nature Communications 103d 1 tweets
The cellular composition of recurrent tumors can provide insight into resistance to therapy and inform on second line therapies. Here, using a genetically modified mouse, the authors perform barcoding experiments of the primary tumors to allow them...
1
NatureRevClinOncol Cellular barcoding study reveals several distinct routes of #breastcancer recurrence, although ~50% have mostly clonal recurrences that are often dependent on MET gene amplification, whereas subclonal recurrences are dependent upon the JAK/STAT pathway 103d
Collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis
eLife 104d 1 tweets
Inhibition of ITGA2-mediated cancer cell-collagen interaction or targeting focal adhesion kinase activity may present an opportunity for therapeutic intervention of metastatic spread in ovarian cancer.
1
NatureRevClinOncol Studies using preclinical models and patient samples suggest that the collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis of ovarian cancer: #GynCSM #camets 104d
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm
Journal of Clinical Oncology 110d 2 tweets
PURPOSE With increasing therapeutic alternatives available, there is growing interest in tools that accurately identify patients most suitable for intensive acute myeloid leukemia (AML) chemotherapy. Nowadays, conceptual criteria proposed by an...
1
NatureRevClinOncol Ferrara unfitness criteria provide a good prediction tool for shorter-term mortality after intensive AML chemotherapy (AUC values of 0.76 and 0.79 for 28-day and 100-day mortality): #leusm #hemeonc 105d
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Nature Medicine 105d 6 tweets
Neoadjuvant immunotherapy combination in the NABUCCO trial elicits high pathological complete response rates in patients with locoregionally advanced (stage III) urothelial cancer and provides molecular biomarkers of treatment efficacy.
2
NatureRevClinOncol Two studies of different PD-(L)1 plus CTLA4 inhibitor combinations as neoadjuvant therapy for locally advanced/high-risk urothelial cancer reveal pCR rates of 37.5% to 46%; 21-55% of pts had grade 3 or higher irAEs: & #blcsm 105d
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
Nature Medicine 105d 4 tweets
Neoadjuvant combination of immune checkpoint therapy in patients with cisplatin-ineligible bladder cancer achieves clinical efficacy and uncovers immune features as potential predictive biomarkers of treatment response.
2
NatureRevClinOncol Two studies of different PD-(L)1 plus CTLA4 inhibitor combinations as neoadjuvant therapy for locally advanced/high-risk urothelial cancer reveal pCR rates of 37.5% to 46%; 21-55% of pts had grade 3 or higher irAEs: & #blcsm 105d
Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives
Nature Reviews Clinical Oncology 106d 3 tweets
Despite the introduction of novel therapies, lung cancer remains the leading cause of cancer-related mortality worldwide. Randomized controlled trials of low-dose CT-based lung cancer screening in high-risk populations have shown a reduction in...
1
NatureRevClinOncol in a Review now live, Matthijs Oudkerk and an international team of co-autors discuss how screening programmes can reduce #lungcancer mortality 106d
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Nature Medicine 113d 9 tweets
Single-cell transcriptomics reveals that the heterogeneity of anti-CD19 CAR T cell infusion products contributes to variability in clinical response, early molecular response and development of immune effector cell-associated neurotoxicity syndrome...
1
NatureRevClinOncol Single-cell seq of axicabtagene CAR T cell infusions used in pts with LBCL shows association between high CD8+ T cell freq & better responses, and CD8+ exhaustion signatures & worse resp. A monocyte-like transc sign was associated with high-grade ICANS 109d
Phase 1 Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia
Clinical Cancer Research 115d 2 tweets
Purpose: Alvocidib is a cyclin-dependent kinase-9 inhibitor leading to down-regulation of the anti-apoptotic BCL-2 family member, MCL-1. Alvocidib has shown clinical activity in a timed-sequential regimen with cytarabine and mitoxantrone in...
1
NatureRevClinOncol in a ph I trial, patients with newly diagnosed AML and ≤65 y of age received the CDK9 inh alvocidib followed by the 7+3 induction regimen. Freq of most common grade ≥3 non-haematol AEs: 44% and 34%. 69% of pts had CR; 8 of 9 patients with a CR had no MRD 110d
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Nature Medicine 113d 4 tweets
The randomized phase 2 trial S1320 comparing different dosing schedules of BRAF/MEK inhibitor combination in BRAF-mutated advanced melanoma shows intermittent therapy does not result in superior progression-free survival in patients.
1
NatureRevClinOncol a phase II study involving pts with BRAFV600-mut melanoma compared continuos and intermittent dosing of BRAF + MEK inh. Median PFS was 9.0 mo vs 5.5 mo in favour of the cont therapy group. Risk of grade ≥3 AEs was higher with cont therapy (45% vs 34%) 110d
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC | NEJM
New England Journal of Medicine 116d 7 tweets
Original Article from The New England Journal of Medicine — Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
1
NatureRevClinOncol In IMpower110 (atezolizumab vs chemo 1st line for patients with PD-L1+ met NSCLC), mOS was 20.2 mo vs 13.1 mo (HR for death 0.59; P = 0.01). Grade 3-4 AEs occurred in 30.1% vs 52.5% of the patients 112d
FDA approves nivolumab and ipilimumab for unresectable malignant pleur
U.S. Food and Drug Administration 116d 4 tweets
FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma
1
NatureRevClinOncol On Oct 2nd, the FDA approved first-line nivolumab plus ipilimumab for adult patients with unresectable malignant pleural #mesothelioma on the basis of results from CHECKMATE-743 113d
Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma
Nature Communications 118d 1 tweets
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer with poor prognosis. Here the authors performed multi-omics analysis of human samples to investigate the mutational landscape of PSC and show three subgroups of PSC with distinct...
1
NatureRevClinOncol Integrated molecular characterization reveals three subsets of pulmonary sarcomatoid carcinoma with molecular similarities to specific subtypes of conventional lung cancer, two of which are enriched for actionable mutations & have T-cell inflamed TME 118d
Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity
Nature Communications 120d 1 tweets
Cardiotoxic adverse events associated with kinase inhibitors are a growing concern in clinical oncology. Here the authors use cellular transcriptomic responses of human cardiomyocytes treated with protein kinase inhibitors and the associated drug...
1
NatureRevClinOncol Transcriptomic profiling of human cardiac cells can enable prediction of protein kinase inhibitor-associated cardiotoxicity 120d
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study
Annals of Oncology 126d 2 tweets
Initial studies of preoperative checkpoint inhibition before radical cystectomy (RC) have shown promising pathologic complete responses. We aimed to analyze the survival outcomes of patients enrolled in PURE-01 study (NCT02736266).
1
NatureRevClinOncol Data from the PURE-01 study suggest that neoadjuvant pembrolizumab for MIBC is associated with 12- and 24-month EFS of 84.5% and 71.7%, respectively, following radical cystectomy, although the prognosis was less favourable for the ypN+ subgroup: #blcsm 121d